Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | DPEP1 | P16444 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394660 | 0.81 | ACACB (0.31) | ACACB | |
| SCHEMBL2393126 | 0.76 | CPB2 (0.34) | CPB2 | |
| SCHEMBL2393068 | 0.75 | MAP2K1 (0.30) | — | |
| SCHEMBL5463403 | 0.74 | SLC6A4 (0.44) | — | |
| SCHEMBL5455820 | 0.74 | SLC6A2 (0.39) | — | |
| SCHEMBL5453564 | 0.74 | METAP2 (0.38) | — | |
| SCHEMBL5453640 | 0.74 | DPP4 (0.40) | DPEP1 | |
| SCHEMBL6542877 | 0.74 | SLC6A2 (0.39) | — | |
| SCHEMBL3061093 | 0.74 | SCN4A (0.44) | — | |
| SCHEMBL6854233 | 0.74 | SCN4A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9051279-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| US-8969351-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| EP-2640467-B1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2640467-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-8440693-B2 | Substituted isoquinolinones and quinazolinones | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2516009-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| WO-2012066095-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | CPB2 4488/4885DPEP1 3420/4885ACACB 3703/4885 |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | MDM4, TP53, TP53BP1 | CPB2 3262/4885DPEP1 1195/4885ACACB 3246/4885 |
| US-20130281473-A1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | MDM4, MDM2, TP53 | CPB2 4488/4885DPEP1 3420/4885ACACB 3703/4885 |
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | MDM4, TP53, TP53BP1 | CPB2 3236/4885DPEP1 1249/4885ACACB 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.